Tarsus Pharmaceuticals, Inc. TARS Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber.
The official record: Tarsus Pharmaceuticals, Inc.’s 10-K, filed February 23, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tarsus Pharmaceuticals, Inc.'s share-based compensation arrangement by share-based payment award, options, vested and expected to vest, outstanding, number.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tarsus Pharmaceuticals, Inc.'s share-based compensation arrangement by share-based payment award, options, vested and expected to vest, outstanding, number?
- Tarsus Pharmaceuticals, Inc. (TARS) reported share-based compensation arrangement by share-based payment award, options, vested and expected to vest, outstanding, number of $3.87M in Q4 2025.
- How has Tarsus Pharmaceuticals, Inc.'s share-based compensation arrangement by share-based payment award, options, vested and expected to vest, outstanding, number changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s share-based compensation arrangement by share-based payment award, options, vested and expected to vest, outstanding, number increased by 15.5% year-over-year, from $3.35M to $3.87M.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s share-based compensation arrangement by share-based payment award, options, vested and expected to vest, outstanding, number?
- Over 5 years (2020 to 2025), Tarsus Pharmaceuticals, Inc.'s share-based compensation arrangement by share-based payment award, options, vested and expected to vest, outstanding, number has grown at a 55.3% compound annual growth rate (CAGR), from $428.49K to $3.87M.